Shire (NASDAQ:SHPG) received a $222.00 price objective from equities researchers at Cantor Fitzgerald in a research report issued to clients and investors on Monday. The brokerage presently has a “buy” rating on the biopharmaceutical company’s stock. Cantor Fitzgerald’s target price indicates a potential upside of 44.32% from the stock’s previous close.
Several other equities analysts have also recently issued reports on SHPG. Liberum Capital restated a “hold” rating on shares of Shire in a research note on Wednesday, December 20th. ValuEngine cut shares of Shire from a “buy” rating to a “hold” rating in a research note on Sunday, December 31st. Zacks Investment Research cut shares of Shire from a “hold” rating to a “sell” rating in a research note on Tuesday, January 2nd. Piper Jaffray reiterated a “hold” rating on shares of Shire in a research note on Wednesday, January 3rd. Finally, Cowen set a $225.00 price objective on shares of Shire and gave the stock a “buy” rating in a research note on Friday, January 5th. One research analyst has rated the stock with a sell rating, eight have issued a hold rating and twelve have issued a buy rating to the stock. The stock presently has an average rating of “Buy” and an average price target of $204.00.
SHPG opened at $153.83 on Monday. The company has a current ratio of 0.97, a quick ratio of 0.55 and a debt-to-equity ratio of 0.46. The stock has a market cap of $47,548.18, a price-to-earnings ratio of 10.15, a P/E/G ratio of 1.23 and a beta of 1.30. Shire has a 52-week low of $123.73 and a 52-week high of $192.15.
Shire (NASDAQ:SHPG) last posted its earnings results on Wednesday, February 14th. The biopharmaceutical company reported $3.98 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $3.86 by $0.12. The business had revenue of $4.14 billion for the quarter. Shire had a net margin of 28.17% and a return on equity of 14.19%. Shire’s revenue was up 8.9% on a year-over-year basis. During the same quarter in the prior year, the company posted $3.37 EPS. analysts expect that Shire will post 15.23 EPS for the current year.
A number of institutional investors have recently added to or reduced their stakes in the stock. CNB Bank purchased a new stake in Shire in the 4th quarter worth approximately $349,000. Delek Group Ltd. purchased a new stake in Shire in the 4th quarter worth approximately $19,478,000. Sawtooth Solutions LLC purchased a new stake in Shire in the 4th quarter worth approximately $200,000. Fore Capital LLC purchased a new stake in Shire in the 4th quarter worth approximately $527,000. Finally, APCM Wealth Management for Individuals purchased a new stake in Shire in the 4th quarter worth approximately $491,000. 19.59% of the stock is owned by institutional investors.
COPYRIGHT VIOLATION NOTICE: This article was first posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this article on another publication, it was stolen and reposted in violation of US and international copyright law. The original version of this article can be viewed at https://www.dispatchtribunal.com/2018/04/11/shire-shpg-given-a-222-00-price-target-at-cantor-fitzgerald.html.
Shire Company Profile
Shire plc, a biotechnology company, researches, develops, licenses, manufactures, markets, distributes, and sells specialist medicines for people with rare diseases and other specialized conditions worldwide. The company offers products in therapeutic areas, including hematology, genetic diseases, neuroscience, immunology, internal medicine, ophthalmology, and oncology.
Receive News & Ratings for Shire Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire and related companies with MarketBeat.com's FREE daily email newsletter.